Keywords: gsk, tykerb, rival, herceptin, ph, iii, study
GSK's Tykerb 'to rival Herceptin,' Ph III study
Article | 12 June 2006
UK drug major GlaxoSmithKline says that its investigational anticancer drug Tykerb (lapatinib ditosylate) increases life expectancy in breast cancer patients ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
